24 related articles for article (PubMed ID: 38511642)
1. 1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma.
Johnson TS; Sudha P; Liu E; Becker N; Robertson S; Blaney P; Morgan G; Chopra VS; Dos Santos C; Nixon M; Huang K; Suvannasankha A; Zaid MA; Abonour R; Walker BA
Nat Commun; 2024 May; 15(1):4144. PubMed ID: 38755140
[TBL] [Abstract][Full Text] [Related]
2. Identifying 1q amplification and PHF19 expressing high-risk cells associated with relapsed/refractory multiple myeloma.
Johnson TS; Sudha P; Liu E; Blaney P; Morgan G; Chopra VS; Santos CD; Nixon M; Huang K; Suvannasankha A; Zaid MA; Abonour R; Walker BA
Res Sq; 2023 Aug; ():. PubMed ID: 37645789
[TBL] [Abstract][Full Text] [Related]
3. PHD finger protein 19 expression in multiple myeloma: Association with clinical features, induction therapy outcome, disease progression, and survival.
Li Y; Gong J; Zhang L
J Clin Lab Anal; 2021 Sep; 35(9):e23910. PubMed ID: 34390275
[TBL] [Abstract][Full Text] [Related]
4. Cell division cycle 37 change after bortezomib-based induction therapy helps to predict clinical response and prognosis in multiple myeloma patients.
Lin W; Chen X; Zheng H; Cai Z
Hematology; 2023 Dec; 28(1):2231741. PubMed ID: 37409850
[TBL] [Abstract][Full Text] [Related]
5. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
6. Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a.
Yu T; Du C; Ma X; Sui W; Yu Z; Liu L; Zhao L; Li Z; Xu J; Wei X; Zhou W; Deng S; Zou D; An G; Tai YT; Tricot G; Anderson KC; Qiu L; Zhan F; Hao M
Mol Cancer Res; 2020 Jul; 18(7):1063-1073. PubMed ID: 32312841
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ
Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806
[TBL] [Abstract][Full Text] [Related]
8. PHF19 before and post induction treatment possess favorable potency of reflecting treatment response to protease inhibitors, event-free survival, and overall survival in multiple myeloma patients.
An H; Chen S; Zhang X; Ke S; Ke J; Lu Y
Hematology; 2024 Dec; 29(1):2331389. PubMed ID: 38511642
[TBL] [Abstract][Full Text] [Related]
9. Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer.
Ghamlouch H; Boyle EM; Blaney P; Wang Y; Choi J; Williams L; Bauer M; Auclair D; Bruno B; Walker BA; Davies FE; Morgan GJ
J Exp Clin Cancer Res; 2021 Dec; 40(1):380. PubMed ID: 34857028
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and Management of Multiple Myeloma: A Review.
Cowan AJ; Green DJ; Kwok M; Lee S; Coffey DG; Holmberg LA; Tuazon S; Gopal AK; Libby EN
JAMA; 2022 Feb; 327(5):464-477. PubMed ID: 35103762
[TBL] [Abstract][Full Text] [Related]
11. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
12. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies.
Naumann-Winter F; Greb A; Borchmann P; Bohlius J; Engert A; Schnell R
Cochrane Database Syst Rev; 2012 Oct; 10():CD004626. PubMed ID: 23076906
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
